The companies on the front edge of pharmaceutical development have identified the value of massive data sets in the future of drug design. Ironically, personalization of therapies will be improved tremendously through examination of massive data sets. Dr. Michael Zaizac from Novartis of Europe discusses how his company has they have integrated artificial intelligence and analysis of patient data sets for new discoveries in patient care.